Treatment of pure aortic regurgitation (AR) has historically been addressed via surgical aortic valve repair or replacement. A less invasive option for patients affected by AR has been attempted with the advent of transcatheter aortic valve replacement (TAVR). Here, we review the rationale, benefits and challenges of TAVR for the treatment of native pure AR. In particular, we explore upcoming dedicated technologies with labelling for transcatheter treatment of AR, detailing both device and procedural specifics. Finally, evidence from recent studies conducted in patients with pure AR is appraised in light of available evidence from TAVR with non-dedicated devices in this setting.
Leone et al. (Tue,) studied this question.